
Embecta Corp (EMBC) Stock Forecast & Price Target
Embecta Corp (EMBC) Analyst Ratings
Bulls say
Embecta is the global market leader in insulin administration products, producing ~8B units annually and distributing products in more than 100 countries. With a focus on generating cash, paying down debt, and returning cash to shareholders, the company's strong portfolio of marketed products and contract manufacturing services put it in a favorable position for long-term success in the diabetes care market. While recent commercial execution stumbles and declining profitability metrics raise some concerns, potential for growth in China and the company's new share buyback program suggest positive potential for investors.
Bears say
Embecta is facing commercial execution uncertainties and a disappointing profitability outlook, resulting in a downgrade from Buy to Neutral. While they have a broad portfolio of products and a strong global presence, the recent dividend cut and lower FCF generation expectations, along with lingering headwinds, have raised concerns about the company's financials. Additionally, the potential for competition, pricing pressure, and shifting market dynamics pose risks to the company's future performance.
This aggregate rating is based on analysts' research of Embecta Corp and is not a guaranteed prediction by Public.com or investment advice.
Embecta Corp (EMBC) Analyst Forecast & Price Prediction
Start investing in Embecta Corp (EMBC)
Order type
Buy in
Order amount
Est. shares
0 shares